Study of GXV813 for Hospitalized Adults with Schizophrenia
This study is testing a drug called GXV813 to see if it is safe, tolerable, and effective for adults hospitalized with schizophrenia. You might be able to join if you are between 18 and 65 years old and have a diagnosis of schizophrenia. Participants will receive either GXV813 or a placebo (an inactive substance). Researchers will measure how your symptoms change using a tool called the Positive and Negative Symptom Scale (PANSS) over 6 weeks to see if GXV813 helps. The study is currently unclear about its recruitment status and plans to enroll 142 participants.
- Study design
- This is an interventional study involving 142 planned participants. It compares the drug GXV813 to a placebo.
- What's involved
- Not specified in the trial record.
- Compensation
- Not stated in the trial record.
- Follow-up
- The primary outcome is measured at Week 6.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
Study to Assess the Safety, Tolerability, and Treatment Response of GXV813 in Hospitalized Adults With Schizophrenia
At a glance
Conditions
Where it's being run
16 sites across 8 statesWho to contact
Opens a ready-to-send draft in your own email app — review before sending.
What this trial measures
- Change from baseline in Positive and Negative Symptom Scale (PANSS) total scoreBaseline, Week 6
PANSS is a 30-item rating scale used to assess the positive, negative, and general psychopathy symptoms of schizophrenia. PANSS total score ranges from 30 to 120 , where a higher score indicates greater severity.